Table 3

12-Month Clinical Outcomes for Overall Population and Patients With Standard Versus Extended-Use Clinical and Lesion Characteristics

Overall (n = 7,832)Standard-Use (n = 2,125)Extended-Use (n = 6,189)p Value (Standard- vs. Extended-Use)
Death (all)2.4 (191)1.2 (24)2.9 (167)<0.001
 Cardiac1.7 (135)0.9 (19)2.0 (116)<0.001
MI (all)1.6 (128)0.7 (15)1.9 (113)<0.001
 Q-wave0.4 (31)0.2 (4)0.5 (27)0.147
 Non–Q-wave1.3 (98)0.5 (11)1.5 (87)0.001
Death (cardiac) + MI (all)3.0 (238)1.5 (30)1.6 (208)0.001
ARC definite stent thrombosis0.6 (49)0.1 (3)0.8 (46)<0.001
 0–30 days0.4 (28)0.1 (2)0.4 (26)0.028
 31–365 days0.3 (23)0.0 (1)0.4 (22)0.015
ARC definite + probable stent thrombosis1.1 (88)0.4 (9)1.4 (79)<0.001
 0–30 days0.8 (59)0.4 (8)0.9 (51)0.035
 31–365 days0.4 (31)0.0 (1)0.5 (30)0.002
All ARC stent thrombosis1.8 (144)0.8 (16)2.2 (128)<0.001
 0–30 days0.8 (59)0.4 (8)0.9 (51)0.035
 31–365 days1.1 (89)0.4 (9)1.4 (80)<0.001
Per protocol stent thrombosis1.0 (82)0.4 (9)1.3 (73)0.001
 0–30 days0.8 (62)0.4 (8)0.9 (54)0.019
 31–365 days0.3 (21)0.0 (1)0.3 (20)0.024
TLR4.5 (349)2.8 (56)5.0 (293)<0.001
TVR4.9 (387)3.0 (61)5.6 (326)<0.001
TVR (nontarget lesion)0.7 (52)0.3 (6)0.8 (46)0.017
TVF7.2 (565)4.3 (87)8.2 (478)<0.001
MACE7.5 (587)4.3 (87)8.6 (500)<0.001

Values are % (n).

ARC = Academic Research Consortium; MACE = major adverse cardiac events; MI = myocardial infarction; TLR = target lesion revascularization; TVF = target vessel failure; TVR = target vessel revascularization.